AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39330966 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose of PCV13
Number of subjects: 7
Study 39330966 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% dose of PCV13
Number of subjects: 7
Study 39330966 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% dose of PCV13
Number of subjects: 7
Study 39330966 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose of PCV10
Number of subjects: 7
Study 39330966 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% dose of PCV10
Number of subjects: 7
Study 39330966 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% dose of PCV10
Number of subjects: 7
Study 39330966 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose of PCV10 (three primary doses without a booster)
Number of subjects: 7
Study 39330966 — intervention group
Group type: COMPARATOR
Intervention: Vaccine-serotype carriage
Number of subjects: 7
Study 39331127 — intervention group
Group type: EXPERIMENTAL
Intervention: TachoSil® as a ventricular sealant
Number of subjects: 39
Study 39331131 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic treatment
Number of subjects: 209
Study 39331131 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 209
Study 39331218 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 80
Study 39331218 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab
Number of subjects: 80
Study 39331218 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab
Number of subjects: 80
Study 39331218 — intervention group
Group type: COMPARATOR
Intervention: topical therapy or methotrexate
Number of subjects: 80
Study 39331218 — intervention group
Group type: COMPARATOR
Intervention: healthy controls
Number of subjects: 80
Study 39331462 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine use of a 3D mapping system during right-sided ablation
Number of subjects: 680
Study 39331462 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero fluoroscopy exposure
Number of subjects: 680
Study 39331462 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal fluoroscopic exposure techniques
Number of subjects: 680
Study 39331470 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisense Oligonucleotides
Number of subjects: 0
Study 39331470 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39331638 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 425
Study 39331638 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg
Number of subjects: 425
Study 39331638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425
Study 39331638 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg and 100 mg
Number of subjects: 425
Study 39331638 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg
Number of subjects: 425
Study 39331638 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib and Adalimumab
Number of subjects: 425
Study 39331724 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab and lenalidomide (D-R) maintenance therapy
Number of subjects: 200
Study 39331724 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care lenalidomide (R) alone
Number of subjects: 200
Study 39331837 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) therapy
Number of subjects: 0
Study 39331837 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EVR with decreased doses of calcineurin inhibitors (tacrolimus, cyclosporine)
Number of subjects: 0
Study 39331837 — intervention group
Group type: EXPERIMENTAL
Intervention: EVR TDM for pancreatic and islet transplantation
Number of subjects: 0
Study 39331837 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic monitoring of EVR
Number of subjects: 0
Study 39332270 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate OSA group (AHI 15-30)
Number of subjects: 51
Study 39332270 — intervention group
Group type: COMPARATOR
Intervention: Nil-mild OSA group (AHI <15)
Number of subjects: 51
Study 39332395 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone (titrated to either 20 mg or 40 mg)
Number of subjects: 6001
Study 39332395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6001
Study 39332418 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273.222 (50 μg dose)
Number of subjects: 379
Study 39332633 — intervention group
Group type: EXPERIMENTAL
Intervention: Vunakizumab 240 mg
Number of subjects: 690
Study 39332633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 690
Study 39332892 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe ROP (n=3130)
Number of subjects: 19863
Study 39332892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral injury (n=2836)
Number of subjects: 19863
Study 39332892 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe ROP and Cerebral injury (n=1438)
Number of subjects: 19863
Study 39332900 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management (MM) with spontaneous recanalization (SR)
Number of subjects: 184
Study 39332900 — intervention group
Group type: COMPARATOR
Intervention: Medical management (MM) without spontaneous recanalization (SR)
Number of subjects: 184
Study 39332900 — intervention group
Group type: COMPARATOR
Intervention: Endovascular therapy (EVT) recanalization
Number of subjects: 184
Study 39333103 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-T cells derived from central memory cells of healthy donors
Number of subjects: 0
Study 39333103 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-expression of KLF7 in CAR-T cells
Number of subjects: 0
Study 39333103 — intervention group
Group type: EXPERIMENTAL
Intervention: Histone mark analyses
Number of subjects: 0
Study 39333315 — intervention group
Group type: EXPERIMENTAL
Intervention: autologous anti-CD123 CAR T cells
Number of subjects: 12
Study 39333450 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk LARC with NAT (HiN)
Number of subjects: 381
Study 39333450 — intervention group
Group type: COMPARATOR
Intervention: High-risk LARC with primary surgery (HiS)
Number of subjects: 381
Study 39333450 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk LARC with NAT (LoN)
Number of subjects: 381
Study 39333450 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk LARC with primary surgery (LoS)
Number of subjects: 381
Study 39333450 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage surgery
Number of subjects: 381
Study 39333450 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-site recurrence
Number of subjects: 381
Study 39333450 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant treatment after primary surgery
Number of subjects: 381
Study 39333875 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant
Number of subjects: 133
Study 39333902 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel semi-facial respirator with chitosan nanoparticles
Number of subjects: 230
Study 39333902 — intervention group
Group type: COMPARATOR
Intervention: Conventional N95 respirator
Number of subjects: 230
Study 39333909 — intervention group
Group type: COMPARATOR
Intervention: Anti-Spike IgG antibody levels in the control group
Number of subjects: 3693
Study 39333909 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Spike IgG antibody levels in specific populations
Number of subjects: 3693
Study 39333909 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-RBD IgG antibody levels in specific populations
Number of subjects: 3693
Study 39333909 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralizing antibodies in specific populations
Number of subjects: 3693
Study 39333909 — intervention group
Group type: COMPARATOR
Intervention: Cumulative probabilities of SARS-CoV-2 infections at five months after serological measurement in specific populations
Number of subjects: 3693
Study 39333909 — intervention group
Group type: COMPARATOR
Intervention: Cumulative probabilities of SARS-CoV-2 infections at five months after serological measurement in control group
Number of subjects: 3693
Study 39333930 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard education + planning intervention
Number of subjects: 30
Study 39333930 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented physical activity education + planning intervention
Number of subjects: 30
Study 39333930 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 30
Study 39333981 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic implementation strategies (educational meeting with nurses, formal implementation blueprint, develop/distribute educational materials)
Number of subjects: 120
Study 39333981 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced implementation strategies (all basic strategies plus auditing/providing feedback and ongoing training for nurses)
Number of subjects: 120
Study 39333981 — intervention group
Group type: EXPERIMENTAL
Intervention: MINISTOP 3.0 app
Number of subjects: 120
Study 39333981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness evaluation of MINISTOP 3.0
Number of subjects: 120
Study 39333981 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustainability assessment of MINISTOP 3.0
Number of subjects: 120
Study 39333981 — intervention group
Group type: EXPERIMENTAL
Intervention: Determinants of effectiveness of MINISTOP 3.0
Number of subjects: 120
Study 39333988 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib at 12 mg once daily (QD) and S-1 at 60 mg twice daily (BID) for 2 weeks, followed by a 1-week treatment-free interval, then maintenance therapy with S-1 monotherapy at 60 mg BID for 2 weeks, followed by a 1-week treatment-free interval until disease progression.
Number of subjects: 52
Study 39334005 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic MRI-based tumor habitat analysis following CCRT.
Number of subjects: 0
Study 39334005 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatiotemporal habitats of the tumor evaluated using diffusion-weighted imaging and dynamic susceptibility contrast imaging.
Number of subjects: 0
Study 39334026 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP) augmented with transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 0
Study 39334026 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP) augmented with closed-loop amplitude-modulated transcranial alternating current stimulation (CLAM-tACS)
Number of subjects: 0
Study 39334026 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness-based relapse prevention (MBRP)
Number of subjects: 0
Study 39334026 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 39334032 — intervention group
Group type: EXPERIMENTAL
Intervention: CAB-LA
Number of subjects: 621
Study 39334032 — intervention group
Group type: COMPARATOR
Intervention: Oral PrEP
Number of subjects: 621
Study 39334042 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvisational music therapy for 12 weeks
Number of subjects: 200
Study 39334042 — intervention group
Group type: COMPARATOR
Intervention: Support as usual
Number of subjects: 200
Study 39334053 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (98.7% of patients) including risperidone (83.6%) with a mean dose of 8.0 ± 5.9 mg/day
Number of subjects: 317
Study 39334053 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antipsychotics with benzodiazepines (34.5%)
Number of subjects: 317
Study 39334053 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antipsychotics with antidepressants (14.4%)
Number of subjects: 317
Study 39334053 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antipsychotics with antidepressants and benzodiazepines (25.9%)
Number of subjects: 317
Study 39334053 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic monotherapy (17.9%)
Number of subjects: 317
Study 39334053 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 317
Study 39334075 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing-led educational program
Number of subjects: 60
Study 39334106 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital (smartphone application) and printed (brochure) tools
Number of subjects: 236
Study 39334106 — intervention group
Group type: COMPARATOR
Intervention: Printed brochure alone (usual service)
Number of subjects: 236
Study 39334111 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exposure prophylaxis awareness
Number of subjects: 324
Study 39334111 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to use Pre-exposure prophylaxis
Number of subjects: 324
Study 39334111 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior use of Pre-exposure prophylaxis
Number of subjects: 324
Study 39334117 — intervention group
Group type: COMPARATOR
Intervention: Systematic nurse-led CGA (arm 1)
Number of subjects: 634
Study 39334117 — intervention group
Group type: COMPARATOR
Intervention: GP-led CGA (arm 2)
Number of subjects: 634
Study 39334117 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care (arm 3)
Number of subjects: 634
Study 39334118 — intervention group
Group type: EXPERIMENTAL
Intervention: CRC screening decision aid
Number of subjects: 42
Study 39334120 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving-based psychological intervention administered face-to-face (PSPI-P)
Number of subjects: 212
Study 39334120 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving-based psychological intervention by telephone multiconference (PSPI-M)
Number of subjects: 212
Study 39334120 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving-based psychological intervention via smartphone app (PSPI-A)
Number of subjects: 212
Study 39334120 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group (UCCG)
Number of subjects: 212
Study 39334120 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving-based psychological intervention (all formats)
Number of subjects: 212
Study 39334129 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin plus a post-PCI high-dose infusion for 2-4 hours
Number of subjects: 6016
Study 39334129 — intervention group
Group type: COMPARATOR
Intervention: Heparin monotherapy
Number of subjects: 6016
Study 39334129 — intervention group
Group type: EXPERIMENTAL
Intervention: Bail-out GPI
Number of subjects: 6016
Study 39334129 — intervention group
Group type: COMPARATOR
Intervention: Heparin with bail-out GPI
Number of subjects: 6016
Study 39334156 — intervention group
Group type: EXPERIMENTAL
Intervention: Early childhood development (ECD) sessions offered in 25 sites (T)
Number of subjects: 9408
Study 39334156 — intervention group
Group type: EXPERIMENTAL
Intervention: ECD sessions with take-home play materials in Cycle 2 (T+)
Number of subjects: 9408
Study 39334156 — intervention group
Group type: COMPARATOR
Intervention: Existing child health and nutrition program (PARN)
Number of subjects: 9408
Study 39334184 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic-induced isolation
Number of subjects: 188
Study 39334184 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pandemic pain interference
Number of subjects: 188
Study 39334184 — intervention group
Group type: EXPERIMENTAL
Intervention: Social isolation interventions
Number of subjects: 188
Study 39334205 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive or cytotoxic therapy
Number of subjects: 491
Study 39334205 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitors
Number of subjects: 491
Study 39334205 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroids
Number of subjects: 491
Study 39334205 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 491
Study 39334205 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 491
Study 39334205 — intervention group
Group type: EXPERIMENTAL
Intervention: FVC % predicted
Number of subjects: 491
Study 39334205 — intervention group
Group type: EXPERIMENTAL
Intervention: DLco % predicted
Number of subjects: 491
Study 39334205 — intervention group
Group type: EXPERIMENTAL
Intervention: St. George's Respiratory Questionnaire total score
Number of subjects: 491
Study 39334205 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 491
Study 39334218 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily bilateral hamstring stretching exercises for six weeks
Number of subjects: 26
Study 39334218 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-cessation (four weeks after stopping stretching)
Number of subjects: 26
Study 39334224 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed tranexamic acid administration (Group-GDT)
Number of subjects: 764
Study 39334224 — intervention group
Group type: COMPARATOR
Intervention: Preemptive tranexamic acid administration (Group-P)
Number of subjects: 764
Study 39334260 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin (AZI) 20 mg/kg bodyweight administered at 6 weeks, 9 months, and 15 months of age
Number of subjects: 20560
Study 39334260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20560
Study 39334260 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin (AZI)
Number of subjects: 20560
Study 39334264 — intervention group
Group type: EXPERIMENTAL
Intervention: Recently stopped users (n=122)
Number of subjects: 990
Study 39334264 — intervention group
Group type: COMPARATOR
Intervention: E-cigarette non-users (n=621)
Number of subjects: 990
Study 39334264 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained users (n=187)
Number of subjects: 990
Study 39334264 — intervention group
Group type: EXPERIMENTAL
Intervention: Recently started users (n=60)
Number of subjects: 990
Study 39334275 — intervention group
Group type: EXPERIMENTAL
Intervention: AR ultrasound (AR-US)
Number of subjects: 47
Study 39334275 — intervention group
Group type: COMPARATOR
Intervention: Standard ultrasound (S-US)
Number of subjects: 47
Study 39334310 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual heart-centred meditation (Christian or Islamic)
Number of subjects: 0
Study 39334310 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (Mindfulness-Based Stress Reduction - MBSR)
Number of subjects: 0
Study 39334310 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study 39334317 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT Fibrinogen Complex, IFC)
Number of subjects: 0
Study 39334317 — intervention group
Group type: COMPARATOR
Intervention: Cryoprecipitated antihemophilic factor (cryo AHF)
Number of subjects: 0
Study 39334335 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic periodontitis with head and neck cancer post-radiotherapy (CP + HNC post-RT)
Number of subjects: 150
Study 39334335 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic periodontitis without head and neck cancer (CP)
Number of subjects: 150
Study 39334335 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 150
Study 39334347 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support tools (DAs)
Number of subjects: 25
Study 39334395 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC601
Number of subjects: 0
Study 39334395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39334411 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Slow Expiration Technique (PSET)
Number of subjects: 42
Study 39334411 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 42
Study 39334432 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised and self-monitored exercise program (NorEx)
Number of subjects: 17
Study 39334468 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin 1.2 MIE q.i.d. for 3 days
Number of subjects: 0
Study 39334468 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin 1.2 MIE q.i.d. for 4 days
Number of subjects: 0
Study 39334468 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin 1.2 MIE q.i.d. for 5 days
Number of subjects: 0
Study 39334468 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin 1.2 MIE q.i.d. for 6 days
Number of subjects: 0
Study 39334468 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin 1.2 MIE q.i.d. for 7 days
Number of subjects: 0
Study 39334472 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based, self-guided positive emotion regulation intervention (ORCHID)
Number of subjects: 300
Study 39337015 — intervention group
Group type: EXPERIMENTAL
Intervention: Nociception Coma Scale-Revised with Personalized Painful Stimulus
Number of subjects: 0
Study 39337015 — intervention group
Group type: COMPARATOR
Intervention: Standard Stimulation
Number of subjects: 0
Study 39337333 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating lymphocyte (TIL) therapy (lifileucel)
Number of subjects: 0
Study 39337423 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical supplementation (olive (poly)phenol, vitamin C, and vitamin B preparation)
Number of subjects: 0
Study 39338117 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Number of subjects: 0
Study 39338117 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39339676 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) adherence in women
Number of subjects: 0
Study 39339676 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) adherence in men
Number of subjects: 0
Study 39339791 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily orange consumption, dosage not specified, duration not specified
Number of subjects: 0
Study 39339810 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics and micronutrients
Number of subjects: 48
Study 39339810 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 48
Study 39340109 — intervention group
Group type: EXPERIMENTAL
Intervention: B.1.351 vaccine
Number of subjects: 208
Study 39340109 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 208
Study 39340164 — intervention group
Group type: EXPERIMENTAL
Intervention: DMT-harmine
Number of subjects: 40
Study 39340164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40